Circulation-Heart Failure

Article	Citations
Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure	174
Unraveling Comorbidities Contribution to Cardiac Diastolic Dysfunction and Heart Failure	166
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program	105
Increased Risk of Congestive Heart Failure Following Carbon Monoxide Poisoning	77
Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy	77
It’s Not You, It’s Me: Uncovering Heart-Kidney Relationship Failures	73
Early Outcomes in Patients With LVAD Undergoing Heart Transplant via Use of the SherpaPak Cardiac Transport System	71
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial	66
Longitudinal Invasive Hemodynamic Assessment in Patients With Acute Decompensated Heart Failure–Related Cardiogenic Shock: A Single-Center Experience	56
Temporary Mechanical Circulatory Support Coordinator: Conception and Implementation of a Novel Role	55
SUSTAINing the Care of Patients With Advanced Heart Failure by Supporting Family Caregivers	54
Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial	52
Identifying the Mechanisms of a Peripherally Limited Exercise Phenotype in Patients With Heart Failure With Preserved Ejection Fraction	48
Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure	48
Diurnal Variations in Natriuretic Peptide Levels: Clinical Implications for the Diagnosis of Acute Heart Failure	48
Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity	44
Why We Should Care About Who Cares for Patients With Heart Failure With Preserved Ejection Fraction	43
Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group	43
Diastolic Dysfunction Is Unmasked on Exercise in Patients With Asymptomatic, Severe Aortic Stenosis: An Invasive Hemodynamic Study	43
Finerenone Improves Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF	42
Impact of Blood Pressure Targets in Patients With Heart Failure Undergoing Postresuscitation Care: A Subgroup Analysis From a Randomized Controlled Trial	40
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials	38
Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial	37
GDMT Optimization, But Make It Patient-Centered: Understanding Patient Needs During Heart Failure Medication Discussions	37
Trending Cardiac Biomarkers During Pregnancy in Women With Cardiovascular Disease	37

Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial	36
Association of Health Insurance Payer Type and Outcomes After Durable Left Ventricular Assist Device Implantation: An Analysis of the STS-INTERMACS Registry	36
Rare Etiology of Cardiogenic Shock in Pregnancy	35
Long-Axis Biplane Echocardiography Sensitively Detects the Progressing Functional Deterioration of Mouse Heart	35
Case Implementing 2022 AHA/ACC/HFSA Guidelines: Heart Failure Management in Pregnancy: Early Planning, Close Surveillance, and Multidisciplinary Care	34
2021: A Look Back	34
Response by Kremer et al to Letter Regarding Article, “Acute Impact of Prone Positioning on the Right Ventricle in COVID-19–Associated Acute Respiratory Distress Syndrome”	32
Peripheral Venous Pressure: An Important but Neglected Contributor to Echocardiographic Estimation of Pulmonary Artery Pressure With Exercise	31
Response by Liang and Shimada to Letter Regarding Article “Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy”	31
Physiologic Insights Into Long COVID Breathlessness	31
Are Men and Women That Different?	29
Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance	29
Potential Novel Therapeutic Target to Improve Graft Survival: New Insights Into the Role of Checkpoint Molecules in Heart Transplant Rejection	29
Circulating MicroRNAs Identify Early Phenotypic Changes in Sarcomeric Hypertrophic Cardiomyopathy	28
Letter by Qiu and Du Regarding Article, “Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”	28
Cardiac Rehabilitation Among Hospitalized Patients With Heart Failure: Eligibility, Enrollment, and Participation	28
Response by Colin-Ramirez et al to Letter Regarding Article, “Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”	27
Natriuretic Peptide Guidance for Post-Myocardial Infarction Care: An Opportunity to Prevent Heart Failure Progression	27
Characteristics of United States Counties in Which Heart Failure Clinical Trials of Pharmacotherapy Were Conducted	27
Epicardial Fat Paradox and Differential Effects of GLP-1 Receptor Agonists Across Heart Failure Phenotypes	26
Case of High Output Heart Failure Caused by Renal Clear Cell Carcinoma	26
Metabolically Healthy/Unhealthy Overweight/Obesity Associations With Incident Heart Failure in Postmenopausal Women	26
Shifting the Shadow of Death	26
Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials	26
Acute Pulmonary Edema During Impella RP Support: Too Much of a Good Thing	26
Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection Fraction	25
Nitric Oxide–Mediated Coronary Endothelial Function Is Impaired in Patients With Heart Failure With Preserved Ejection Fraction	24
Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction	24
Plasma Proteomic Patterns Show Sex Differences in Early Concentric Left Ventricular Remodeling	24
Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies	23
Plasma SVEP1 Levels Predict Cardiovascular Events in Hypertrophic Cardiomyopathy Beyond Conventional Clinical Risk Models Including NT-proBNP	23
Association of Pulmonary Artery Pulsatility Index With Adverse Cardiovascular Events Across a Hospital-Based Sample	23
Cognitive and Procedural Competencies in the Cardiac Intensive Care Unit	23
Unraveling the Role of Myocardial Inflammation in ATTR-CM: A Targetable Mechanism?	23
Reflections on the Win Ratio With Time-to-Event Outcomes	23
Letter by Jha Regarding Article, “Pathophysiologic Vasodilation in Cardiogenic Shock and Its Impact on Mortality”	23
Systemic Circulation in Advanced Heart Failure and Cardiogenic Shock: State-of-the-Art Review	22
Cardiovascular Measures of All-Cause Mortality in Duchenne Muscular Dystrophy	21
Tranexamic Acid in the Treatment of Refractory Gastrointestinal Arteriovenous Malformation Bleeding in Left Ventricular Assist Device Patients	21
Calling for Cooperation and Collaboration in Adult Congenital Heart Disease–Related Heart Failure	21
Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry	20
Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial	20
Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis	20
Challenges Related to Out-of-Pocket Costs in Heart Failure Management	20
Biopsy-Proven Giant Cell Myocarditis Following the COVID-19 Vaccine	20
Protein Biomarkers of Adverse Clinical Features and Events in Sarcomeric Hypertrophic Cardiomyopathy	20
Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure	20
PRKAG2 Syndrome Caused by a Novel Missense Variant Mimicked Sporadic Hypertrophic Cardiomyopathy Until Its Progression to Burned-Out Phase	20
How Did We Score? Evaluating the Utility of a Score-Based System for Heart Failure Medical Therapy	19
Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure	19

Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan	19
National Organ Procurement and Transplant Network Heart Allocation Policy: 6 Years Later	19
Ramping Up the Pressure on the Right Ventricle	19
Change in Caregiver Health-Related Quality of Life From Before to Early After Surgery: SUSTAIN-IT Study	19
Identifying Discordance of Right- and Left-Ventricular Filling Pressures in Patients With Heart Failure by the Clinical Examination	19
Avoiding Catastrophe	19
Serial 99m Technetium Pyrophosphate Scintigraphy and Multimodality Assessments After Different Doses of Tafamidis for Variant Transthyretin Cardiac Amyloidosis	19
High-Intensity Care Versus GDMT Titration: Which Rapidly Improves Health Status in Patients With Heart Failure?	19
Modulation of Pulsatile Left Ventricular Afterload by Renal Denervation in Heart Failure With Preserved Ejection Fraction	19
Letter by Monda and Limongelli Regarding Article, “Changes in Cardiac Function Following Fulminant Myocarditis”	18
Equity in Heart Failure Care: A Get With the Guidelines Analysis of Between- and Within-Hospital Differences in Care by Sex, Race, Ethnicity, and Insurance	18
Nonpharmacological Approaches to Managing Heart Failure With Preserved Ejection Fraction	18
Left Ventricular Gene Expression in Heart Failure With Preserved Ejection Fraction—Profibrotic and Proinflammatory Pathways and Genes	17
REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNA -Related Dilated Cardiomyopathy	17
Framework to Classify Reverse Cardiac Remodeling With Mechanical Circulatory Support: The Utah-Inova Stages	17
Infarct Size Reduction With Cyclosporine A in Circulatory Death Rat Hearts: Reducing Effective Ischemia Time With Therapy During Reperfusion	17
SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension	17
The Great Masquerader: Diagnosing Cardiac Sarcoidosis in the Era of Advanced Cardiac Imaging	17
A Peek Into the Future: Will Serial Multimarker Testing Help Bring a New Era of Precision Medicine in Heart Failure Patients?	17
Common Variants on FGD5 Increase Hazard of Mortality or Rehospitalization in Patients With Heart Failure From the ASCEND-HF Trial	17
Heart Failure With Preserved Ejection Fraction: From a Vascular Perspective	17
Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial	16
Impact of Different Training Modalities on Molecular Alterations in Skeletal Muscle of Patients With Heart Failure With Preserved Ejection Fraction: A Substudy of the OptimEx Trial	16
Pathophysiologic Vasodilation in Cardiogenic Shock and Its Impact on Mortality	16
Response by Denfeld et al to Letter Regarding Article, “Characterizing Sex Differences in Physical Frailty Phenotypes in Heart Failure”	16
Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction	16
Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction	16
Longitudinal Trends in Donor and Recipient Risk Profile, and Clinical Outcomes, for Donation After Circulatory Death Heart Transplantation	16
Correction to: Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop	16
Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences	16
Practice Patterns and Patient Outcomes After Widespread Adoption of Remote Heart Failure Care	15
Disparities in Hospital Length of Stay Across Race and Ethnicity Among Patients With Heart Failure	15
Physical Activity, Sedentary Time, and Heart Failure Risk in Low-Income Black and White Adults Living in the Southeastern United States	15
Cardiogenic Shock Teams: Past, Present, and Future Directions	15
Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial	15
Immunomodulatory Cell Therapy Using αGalCer-Pulsed Dendritic Cells Ameliorates Heart Failure in a Murine Dilated Cardiomyopathy Model	15
Long-Term Outcomes of Early Coronary Artery Disease Testing After New-Onset Heart Failure	15
Outcomes of Combined Heart and Kidney Transplantation Under the New Heart Allocation Policy: A United Organ Network for Organ Sharing Database Analysis	15
Two-Year Follow Up of the LATERAL Clinical Trial	15
Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction	14
Early Outcomes of Heart Transplantation Using Donation After Circulatory Death Donors in the United States	14
Edge-to-Edge Transcatheter Mitral Valve Repair Versus Optimal Medical Treatment in Nonresponders to Cardiac Resynchronization Therapy: The MITRA-CRT Trial	14
Pleural Effusion and Invasive Hemodynamic Measurements in Advanced Heart Failure	14
Challenges for Patients Dying of Heart Failure and Cancer	14
Social Determinants of Health and 30-Day Readmissions Among Adults Hospitalized for Heart Failure in the REGARDS Study	13
Targeting Iron Deficiency in Heart Failure: Existing Evidence and Future Expectations	13
Variation in Left Ventricular Assist Device Postdischarge Caregiver Requirements: Results From a Mixed-Methods Study With Equity Implications	13
Temporal Trends of Heart Failure Hospitalizations in Cardiology Versus Noncardiology Wards According to Ejection Fraction: 16-Year Data From the SwedeHF Registry	13
Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy	13
Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes	13
Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry	13
Enhancing the Prediction of Cardiac Allograft Vasculopathy Using Intravascular Ultrasound and Machine Learning: A Proof of Concept	13
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy	13
Pulmonary Hypertension in Congenital Heart Disease: A Scientific Statement From the American Heart Association	13
Optical Coherence Tomography in Cardiac Allograft Vasculopathy	13
Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure	13
Trajectory of Cognitive Function After Incident Heart Failure	12
Impact of Arteriovenous Fistula Compression on Mitral Regurgitation Severity	12
Increased Chamber Resting Tone Is a Key Determinant of Left Ventricular Diastolic Dysfunction	12
Nonischemic Cardiomyopathy With Myocardial Calcinosis Masquerading as Cardiac Amyloidosis	12
Response by Aronson et al to Letter Regarding Article, “Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure”	12
Precision Medicine Is in the Eye of the Beholder	12
Racial Differences in Donor-Derived Cell-Free DNA and Mitochondrial DNA After Heart Transplantation, on Behalf of the GRAfT Investigators	12
Ubiquity of Multimorbidity: Comorbid Conditions and Mortality in HFpEF	12
Sex and Age Differences in the Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Heart Failure: A Prospective Cohort Study	12
Combined Loss of Obsc and Obsl1 in Murine Hearts Results in Diastolic Dysfunction, Altered Metabolism, and Deregulated Mitophagy	12
The Value of Passive Leg Raise During Right Heart Catheterization in Diagnosing Heart Failure With Preserved Ejection Fraction	12
Psychometric Evaluation of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure	11
Social Constructs and the Making of Social Determinants of Health: A Pathway for Equity Interventions to Change Heart Failure Outcomes	11
Early Use of Phosphodiesterase Inhibitors After Left Ventricular Assist Device: Is It Time to Rethink?	11
Metabolic Profiling Identifies 1-MetHis and 3-IPA as Potential Diagnostic Biomarkers for Patients With Acute and Chronic Heart Failure With Reduced Ejection Fraction	11
Predicted Heart Mass: A Tale of 2 Ventricles	11
Letter by Baldovino et al Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”	11
AHA/ACC/HFSA Guidelines Implementation Case Series: Resynchronization Pacing Preferred in Patients With Reduced Ejection Fraction	11
Predicting 1-Year Mortality in Outpatients With Heart Failure With Reduced Left Ventricular Ejection Fraction: Do Empiric Models Outperform Physician Intuitive Estimates? A Multicenter Cohort Study	11
Response by Park et al to Letter Regarding Article, “Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to	11
You Are Where You Eat: The Local Environment and Risk of Heart Failure	11
Conceptualizing Liberation From Venoarterial Extracorporeal Membrane Oxygenation	10
Practice Patterns After Return of Rare Variants Associated With Cardiomyopathy in the Electronic Medical Records and Genomics Network	10
Response by Marquetand and Reil to Letter Regarding Article, “Invasive and Echocardiographic Characteristics of a Patient With Severe Pulmonary Valve Regurgitation Pretending Severe Pulmonary Stenosis	10

Letter by Haddy Regarding Article, “Invasive and Echocardiographic Characteristics of a Patient With Severe Pulmonary Valve Regurgitation Pretending Severe Pulmonary Stenosis”	10
Coronary Allograft Vasculopathy: From Predictably Unpredictable to Unpredictably Predictable	10
Is There a Logic in Using Device-Based Algorithms to Prevent Heart Failure Decompensations?	10
Cardiomyopathy and Refractory Tachycardia in a Patient With Hereditary Amyloidosis	10
Is My Patient Fit for Surgery? Navigating Between the Rock of Heart Failure and the Hard Place of Semiurgent Surgery	9
Unmasking Transthyretin Cardiac Amyloidosis Following Transcatheter Aortic Valve Implantation	9
Failing to Make the Grade: Conventional Cardiac Allograft Rejection Grading Criteria Are Inadequate for Predicting Rejection Severity	9
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials	9
MiR-150 Attenuates Maladaptive Cardiac Remodeling Mediated by Long Noncoding RNA MIAT and Directly Represses Profibrotic Hoxa4	9
Health-Related Quality of Life in Older Patients With Heart Failure From Before to Early After Advanced Surgical Therapies: Findings From the SUSTAIN-IT Study	9
Clinical Management and Transplant Considerations in Pediatric Pulmonary Hypertension Due to Left Heart Disease: A Scientific Statement From the American Heart Association	9
Is It Primetime for Finerenone in Heart Failure?	9
Impact of Advanced Therapy Centers on Characteristics and Outcomes of Heart Failure Admissions	9
Hospital at Home as a Treatment Strategy for Worsening Heart Failure	9
Quality of Life Trajectory and Its Mediators in Older Patients With Acute Decompensated Heart Failure Receiving a Multi-Domain Rehabilitation Intervention: Results From the Rehabilitation Therapy in O	9
Risk of Worsening Heart Failure and All-Cause Mortality Following COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Real-World Safety Study	9
Letter by ten Berg et al Regarding Article, “Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Regis	9
Association of Patient Reported Outcomes With Caregiver Burden in Older Patients With Advanced Heart Failure: Insights From the SUSTAIN-IT Study	9
Blood Pressure and Glycemic Control Among Ambulatory US Adults With Heart Failure: National Health and Nutrition Examination Survey 2001 to 2018	9
Stress and Coping Among Family Caregivers of Patients With a Destination Therapy Left Ventricular Assist Device: A Multicenter Mixed Methods Study	9
Mixed Shock Complicating Cardiogenic Shock: A Corollary or a Ramification?	9